EUCTR2020-002504-39-DE进行中（未招募）1 期
Hamburg Edoxaban foR anticoagulation in COvid-19 study - HERO-19
niversity Medical Center Hamburg-Eppendorf0 个研究点目标入组 172 人开始时间: 2020年8月14日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 172
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Diagnosis of COVID-19 and hospitalization on ICU, or
- •Diagnosis of COVID-19 and hospitalization on normal ward, or
- •Diagnosis of COVID-19 and troponin = ULN and/or D-dimer =0.5 mg/L
- •Legally effective declaration of informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 59
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 113
排除标准
- •Age below 18
- •Life expectancy less than 3 months before COVID-19
- •Resuscitation > 30 minutes
- •Contraindications against the use of each of the standard LMWH/ Fondaparinux according to the •respective SmPC
- •Hypersensitivity to the active substance, to Edoxaban or any of its excipients
- •Significantly increased bleeding risk
- •Other indication for anticoagulation beyond COVID-19
- •GFR < 15 mL/min
- •Planned transfer of the patient to another clinic within the next 42 days
研究者
相似试验
已完成
3 期
Hamburg Edoxaban for Anticoagulation in COVID-19 StudyCovid19NCT04542408Universitätsklinikum Hamburg-Eppendorf140
进行中（未招募）
3 期
Clinical trial of Edoxaban after surgical bioprosthetic valve replacementJPRN-jRCT2051210209Izumi Chisato450
终止
3 期
CorONa Virus edoxabaN ColchicinE (CONVINCE) COVID-19SARS-CoV InfectionCOVID-19NCT04516941Insel Gruppe AG, University Hospital Bern60
已完成
不适用
Antiseptic gargle in COVID-19U07.1COVID-19, virus identifiedDRKS00024028niversitätsmedizin Rostock152
进行中（未招募）
1 期
Evaluation of Edoxaban in Anticoagulant Naïve patients with normal renal function who are suffering from abnormal and irregular, often rapid heart rate defined as Atrial Fibrillation with no evidence of moderate or severe damage of the heart valves.EUCTR2016-001795-30-LTDaiichi Sankyo, Inc.600